Involvement of neurotransmitters in the 'anxiolytic-like' action of atrial natriuretic peptide in rats

É Bíró, G. Tóth, G. Telegdy

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Effects of centrally administered rat atrial natriuretic peptide (ANP1-28) in different doses (50, 100, 150, 200, 500 or 1000 ng) were examined in rats with respect to anxiolytic properties in an elevated plus-maze model. In doses of 100, 150 and 200 ng, ANP1-28 abolished the normal preference for the closed arms of the maze, and increased the percentage of time spent on the open arms; this is consistent with an 'anxiolytic-like' effect. Doses of 50, 500 and 1000 ng of rANP1-28 produced no behavioral effects in the elevated plus-maze model. Pretreatment with a dopaminergic blocker, an α-adrenoreceptor or a β-adrenoreceptor antagonist antagonized the effect of 200 ng ANP1-28 in the elevated plus-maze test. A muscarinergic cholinergic blocker, a GABA receptor antagonist, a 5-HT receptor antagonist and an opiate antagonist were not able to modulate the 'anxiolytic-like' effects of ANP1-28. These results suggest that a multiple neurotransmitter system activation might be responsible for the ANP1-28-induced 'anxiolytic-like' activity.

Original languageEnglish
Pages (from-to)215-220
Number of pages6
JournalNeuropeptides
Volume29
Issue number4
DOIs
Publication statusPublished - 1995

Fingerprint

Anti-Anxiety Agents
Atrial Natriuretic Factor
Neurotransmitter Agents
Rats
Opiate Alkaloids
GABA Antagonists
Serotonin Antagonists
Serotonin Receptors
Cholinergic Agents
Chemical activation
rat atrial natriuretic peptide

ASJC Scopus subject areas

  • Endocrinology
  • Cellular and Molecular Neuroscience
  • Endocrine and Autonomic Systems
  • Neurology
  • Clinical Neurology
  • Endocrinology, Diabetes and Metabolism
  • Neuroscience(all)
  • Biochemistry

Cite this

Involvement of neurotransmitters in the 'anxiolytic-like' action of atrial natriuretic peptide in rats. / Bíró, É; Tóth, G.; Telegdy, G.

In: Neuropeptides, Vol. 29, No. 4, 1995, p. 215-220.

Research output: Contribution to journalArticle

@article{de8ad3728d3749a193116efdd9a07c06,
title = "Involvement of neurotransmitters in the 'anxiolytic-like' action of atrial natriuretic peptide in rats",
abstract = "Effects of centrally administered rat atrial natriuretic peptide (ANP1-28) in different doses (50, 100, 150, 200, 500 or 1000 ng) were examined in rats with respect to anxiolytic properties in an elevated plus-maze model. In doses of 100, 150 and 200 ng, ANP1-28 abolished the normal preference for the closed arms of the maze, and increased the percentage of time spent on the open arms; this is consistent with an 'anxiolytic-like' effect. Doses of 50, 500 and 1000 ng of rANP1-28 produced no behavioral effects in the elevated plus-maze model. Pretreatment with a dopaminergic blocker, an α-adrenoreceptor or a β-adrenoreceptor antagonist antagonized the effect of 200 ng ANP1-28 in the elevated plus-maze test. A muscarinergic cholinergic blocker, a GABA receptor antagonist, a 5-HT receptor antagonist and an opiate antagonist were not able to modulate the 'anxiolytic-like' effects of ANP1-28. These results suggest that a multiple neurotransmitter system activation might be responsible for the ANP1-28-induced 'anxiolytic-like' activity.",
author = "{\'E} B{\'i}r{\'o} and G. T{\'o}th and G. Telegdy",
year = "1995",
doi = "10.1016/0143-4179(95)90063-2",
language = "English",
volume = "29",
pages = "215--220",
journal = "Neuropeptides",
issn = "0143-4179",
publisher = "Churchill Livingstone",
number = "4",

}

TY - JOUR

T1 - Involvement of neurotransmitters in the 'anxiolytic-like' action of atrial natriuretic peptide in rats

AU - Bíró, É

AU - Tóth, G.

AU - Telegdy, G.

PY - 1995

Y1 - 1995

N2 - Effects of centrally administered rat atrial natriuretic peptide (ANP1-28) in different doses (50, 100, 150, 200, 500 or 1000 ng) were examined in rats with respect to anxiolytic properties in an elevated plus-maze model. In doses of 100, 150 and 200 ng, ANP1-28 abolished the normal preference for the closed arms of the maze, and increased the percentage of time spent on the open arms; this is consistent with an 'anxiolytic-like' effect. Doses of 50, 500 and 1000 ng of rANP1-28 produced no behavioral effects in the elevated plus-maze model. Pretreatment with a dopaminergic blocker, an α-adrenoreceptor or a β-adrenoreceptor antagonist antagonized the effect of 200 ng ANP1-28 in the elevated plus-maze test. A muscarinergic cholinergic blocker, a GABA receptor antagonist, a 5-HT receptor antagonist and an opiate antagonist were not able to modulate the 'anxiolytic-like' effects of ANP1-28. These results suggest that a multiple neurotransmitter system activation might be responsible for the ANP1-28-induced 'anxiolytic-like' activity.

AB - Effects of centrally administered rat atrial natriuretic peptide (ANP1-28) in different doses (50, 100, 150, 200, 500 or 1000 ng) were examined in rats with respect to anxiolytic properties in an elevated plus-maze model. In doses of 100, 150 and 200 ng, ANP1-28 abolished the normal preference for the closed arms of the maze, and increased the percentage of time spent on the open arms; this is consistent with an 'anxiolytic-like' effect. Doses of 50, 500 and 1000 ng of rANP1-28 produced no behavioral effects in the elevated plus-maze model. Pretreatment with a dopaminergic blocker, an α-adrenoreceptor or a β-adrenoreceptor antagonist antagonized the effect of 200 ng ANP1-28 in the elevated plus-maze test. A muscarinergic cholinergic blocker, a GABA receptor antagonist, a 5-HT receptor antagonist and an opiate antagonist were not able to modulate the 'anxiolytic-like' effects of ANP1-28. These results suggest that a multiple neurotransmitter system activation might be responsible for the ANP1-28-induced 'anxiolytic-like' activity.

UR - http://www.scopus.com/inward/record.url?scp=0028866166&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028866166&partnerID=8YFLogxK

U2 - 10.1016/0143-4179(95)90063-2

DO - 10.1016/0143-4179(95)90063-2

M3 - Article

C2 - 8584139

AN - SCOPUS:0028866166

VL - 29

SP - 215

EP - 220

JO - Neuropeptides

JF - Neuropeptides

SN - 0143-4179

IS - 4

ER -